Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
US8642258B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 12, 2006 |
| Grant date | Feb 4, 2014 |
| Priority date | — |
| Expiry date | Jan 21, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55566
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a product named “immunogenical complex”, which comprises an adjuvant characterized by solid particles of highly ordinated nanostructured mesoporous silica, preferably, SBA-15 Silica, and vaccinal antigens of several natures, encapsulated in the referred to adjuvants. The immunogenical complex of the present invention allows the presentation of the antigens that compose it to lymphocytes, in a safe, gradual and extended way, which leads to a more efficient immunological memory, increases the immunogenicity of the antigen and improves the production of antibodies. This ensures an efficient immunological protection with fewer amounts of antigens and/or less repetitions of vaccinal doses. In addition, the characteristics of the immunogenical complex of the present invention promotes effective immunity induction, homogeneous in “god and bad respondent” individuals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.